Effects of murine PR3-ANCAs compared to mock immune serum in LPS-primed and nonprimed mice
Treatment . | No. of affected mice/total no. . | No. with lung capillaritis or alveolar hypercellularity . | No. with glomerulonephritis . | No. with hematuria or leukocyturia . | Urinary protein, mg/dL, mean (SD) . | Urinary albumin, mg/dL, mean (SD) . | Urinary albumin-protein ratio . | Urinary protein-creatinine ratio . |
|---|---|---|---|---|---|---|---|---|
| mPR3-ANCAs | 1/3 | 1 | 0 | 0 | 645 (368) | 94 (29) | 0.18 | 13.5 |
| Mock immune serum | 1/3 | 0 | 1 | 0 | 670 (289) | 103 (37) | 0.16 | 16.5 |
| mPR3-ANCAs + 0.1 mg/kg LPS | 3/5 | 2 | 0 | 1 | 936 (588) | 118 (24) | 0.16 | 12.0 |
| Mock immune serum + 0.1 mg/kg LPS | 1/5 | 1 | 0 | 0 | 847 (362) | 130 (45) | 0.14 | 14.2 |
| mPR3-ANCAs + + 2.5 mg/kg LPS | 3/4 | 2 | 3 | 0 | 744 (292) | 336 (359) | 0.40 | 8.7 |
Treatment . | No. of affected mice/total no. . | No. with lung capillaritis or alveolar hypercellularity . | No. with glomerulonephritis . | No. with hematuria or leukocyturia . | Urinary protein, mg/dL, mean (SD) . | Urinary albumin, mg/dL, mean (SD) . | Urinary albumin-protein ratio . | Urinary protein-creatinine ratio . |
|---|---|---|---|---|---|---|---|---|
| mPR3-ANCAs | 1/3 | 1 | 0 | 0 | 645 (368) | 94 (29) | 0.18 | 13.5 |
| Mock immune serum | 1/3 | 0 | 1 | 0 | 670 (289) | 103 (37) | 0.16 | 16.5 |
| mPR3-ANCAs + 0.1 mg/kg LPS | 3/5 | 2 | 0 | 1 | 936 (588) | 118 (24) | 0.16 | 12.0 |
| Mock immune serum + 0.1 mg/kg LPS | 1/5 | 1 | 0 | 0 | 847 (362) | 130 (45) | 0.14 | 14.2 |
| mPR3-ANCAs + + 2.5 mg/kg LPS | 3/4 | 2 | 3 | 0 | 744 (292) | 336 (359) | 0.40 | 8.7 |